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Purpose: We investigated the disease-free survival (DFS) of HER2-positive primary breast 
cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, as well as predictive 
factors for DFS and pathologic response. 
Patients and methods: Data from 829 female patients treated between 2001 and 2010 were 
collected from 38 institutions in Japan. Predictive factors were evaluated using multivariate 
analyses. 
Results: The 3-year DFS rate was 87% (95% confidence interval [CI] 85-90). The pathologic 
complete response (pCR: ypT0/is + ypN0) rate was 51%. The pCR rate was higher in the 
ER/PgR-negative patients than in the ER/PgR-positive patients (64% vs 36%, P < 0.001). 
Patients with pCR showed a higher DFS rate than patients without pCR (93% vs 82%, P < 
0.001). Multivariate analysis revealed 3 independent predictors for poorer DFS: advanced nodal 
stage (hazard ratio [HR] 2.63, 95%CI 1.36-5.21, P = 0.004 for cN2-3 vs cN0), 
histological/nuclear grade 3 (HR 1.81, 95%CI 1.15-2.91, P = 0.011), and non-pCR (HR 1.98, 
95%CI 1.22-3.24, P = 0.005). In the ER/PgR-negative dataset, non-pCR (HR 2.63, 95%CI 
1.43-4.90, P = 0.002) and clinical tumor stage (HR 2.20, 95%CI 1.16-4.20, P = 0.017 for cT3-4 
vs cT1-2) were independent predictors for DFS, and in the ER/PgR-positive dataset, histological 
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grade of 3 (HR 3.09, 95%CI 1.48-6.62, P = 0.003), clinical nodal stage (HR 4.26, 95%CI 
1.53-13.14, P = 0.005 for cN2-3 vs cN0), and young age (HR 2.40, 95%CI 1.12-4.94, P = 0.026 
for ≤40 vs >40) were negative predictors for DFS. Strict pCR (ypT0 + ypN0) was an 
independent predictor for DFS in both the ER/PgR-negative and -positive datasets (HR 2.66, 
95%CI 1.31-5.97, P = 0.006 and HR 3.86, 95%CI 1.13-24.21, P = 0.029, respectively). 
Conclusions: These results may help assure a more accurate prognosis and personalized 
treatment for HER2-positive breast cancer patients. 
 
Key words: Breast cancer, HER2, neoadjuvant chemotherapy, pathologic complete response, 





Amplification or overexpression of human epidermal growth factor receptor-2 (HER2) is 
associated with a high risk of breast cancer recurrence and metastasis [1]. Adjuvant use of 
cytotoxic chemotherapy and trastuzumab, a recombinant humanized monoclonal antibody that 
targets HER2, improves the overall survival (OS) and disease-free survival (DFS) of patients 
with HER2-positive primary breast cancer [2,3]. 
Neoadjuvant chemotherapy (NAC) reduces tumor size, which improves the rate of 
breast-conserving surgery, and provides information about chemosensitivity that helps with the 
design of postoperative therapy. Several meta-analyses have revealed that patients with a 
pathologic complete response (pCR) after NAC had higher survival rates than those without 
pCR, indicating that pCR represents a surrogate prognostic indicator [4-6]. 
Adding trastuzumab to NAC doubles the rate of pCR in patients with HER2-positive primary 
breast cancer [7-9]. The NOAH trial showed better 3-year event-free survival for chemotherapy 
plus trastuzumab versus chemotherapy alone [8]. In the TECHNO trial, patients with pCR after 
NAC plus trastuzumab showed better 3-year DFS than patients without pCR [10]; however, 
predictors for pCR and survival after treatment are unknown. 
 This multicenter retrospective study investigated the survival after NAC with trastuzumab 
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PATIENTS AND METHODS 
 
Patients 
In this multicenter retrospective cohort study, the inclusion criteria were female sex, 
histologically confirmed HER2-positive invasive breast cancer diagnosed between 2001 and 
2010, no distant metastasis, age 20-70 years, and received NAC containing trastuzumab. 
Eligible patients were identified from the institutional databases. Data were managed by the data 
center of the Japan Breast Cancer Research Group (JBCRG). 
The study protocol was approved by the Institutional Review Board at Kyoto University 
Hospital and participating institutions. All patient data were anonymized and allocated numbers 
according to Japanese ethics guidelines for epidemiologic research. 
 
Pathological assessment 
Pathology specialists at each institution performed the pathological investigation. 
 8 
 
HER2-positive status was defined as 3+ overexpression by immunohistochemical testing or 
HER2 amplification by fluorescent in situ hybridization (HER2/CEP17 ratio ≥ 2.0). At each 
institution, surgical specimens obtained following NAC were serially sectioned, stained with 
haematoxylin and eosin (H&E), and diagnosed by experienced pathologists. pCR was defined 
as the absence of residual invasive cancer cells in the breast and axillary lymph nodes (ypT0/is 
+ ypN0). Strict pCR (spCR), another pCR definition, was defined as no invasive and 
non-invasive residuals in the breast and axillary nodes (ypT0 + ypN0). 
 
Statistical analysis 
All survival outcomes were measured from the date of starting NAC to the date of first event. 
The primary survival outcome was DFS defined as time to occurrence of recurrence, secondary 
malignancy (including contralateral breast cancer, hematological malignancy, and sarcoma), or 
death as a result of any cause. Secondary survival outcomes were OS defined as time to death as 
a result of any cause, distant recurrence-free survival (DRFS) defined as time to any recurrence 
except for ipsilateral breast or regional lymph node, and death as a result of any cause. 
The Kaplan-Meier method was used to estimate survival outcomes. χ2 tests for categorical 
data and log-rank tests for time-to-event endpoints provided two-sided p values, and p values < 
0.05 were considered statistically significant. Cox proportional hazards regression analysis was 
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used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Logistic regression 
was used to estimate odds ratios (ORs) and 95% CIs. Covariates used in the multivariate model 
were age, body mass index, clinical tumor stage, clinical nodal stage, estrogen receptor 
(ER)/progesterone receptor (PgR) status, histological/nuclear grade, pCR/spCR, surgery type, 
radiation therapy, adjuvant hormonal therapy, adjuvant chemotherapy, and adjuvant trastuzumab. 
Menopausal status was not included in the model because of collinearity with age. Patients with 
missing data were excluded from the multivariate analysis (e.g. patients whose adequate 
pathologic responses were not confirmed due to insufficient local therapy or lack of information 
regarding local therapy type). All statistical analyses were performed using JMP® (ver. 10.0.2, 






Data of 829 patients from 38 institutions in Japan were collected. Among them, 53 did not meet 
the inclusion criteria and were excluded, leaving a total of 776 patients for analysis (whole 
dataset). HER2-positive tumors could be subdivided into ER/PgR positive and negative, and we 
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therefore divided the patients into an ER/PgR-positive dataset (N = 334) and ER/PgR-negative 
dataset (N = 439) and also performed the analyses for each dataset (Figure 1). 
Baseline characteristics and treatment of the whole dataset are summarized in Table 1. 
Median age was 53 (range 25-70) years. Most patients had tumor stage T2 (61%) and were 
clinically node positive (67%). ER and PgR were negative in 57% of the patients. Most patients 
received anthracycline- and taxane-containing chemotherapy (87%), and trastuzumab was 
administered concurrently with taxane (80%). Breast-conserving surgery was performed in 64% 
of the patients, most of whom (91%) received radiation therapy. Radiation therapy was 
performed in 35% of the patients who received mastectomy. Adjuvant hormonal therapy was 




The median follow-up period was 42 (interquartile range 30-58) months. For the whole dataset, 
the 3-year DFS rate was 87% (95%CI 85-90) (Figure 2A). Three-year OS and DRFS were 97% 
(95%CI 96-98) and 91% (95%CI 89-93), respectively. pCR was achieved in 399 (51%) patients 
and spCR in 240 (31%) patients.  
The 3-year DFS rate was almost the same among patients in the ER/PgR-positive and 
 11 
 
-negative datasets (87% vs 88%, P = 0.888) (Figure 2B). The pCR and spCR rates were higher 
in the ER/PgR-negative patients than in the ER/PgR-positive patients (64% vs 36% for pCR, P 
< 0.001; 38% vs 23% for spCR, P < 0.001, respectively). 
 
Prognostic factors for survival outcomes 
The results of Cox proportional hazard regression performed to evaluate the prognostic effect of 
baseline characteristics and pathologic tumor response to NAC with trastuzumab are shown in 
Table 2. In the whole dataset, independent predictors for poorer DFS were advanced clinical 
nodal stage (adjusted HR 2.63, 95%CI 1.36-5.21, P = 0.004 for cN2-3 vs cN0; adjusted HR 1.64, 
95%CI 0.91-3.09, P = 0.100 for cN1 vs cN0), histological/nuclear grade 3 (adjusted HR 1.81, 
95%CI 1.15-2.91, P = 0.011), and failure to achieve pCR (adjusted HR 1.98, 95%CI 1.22-3.24, 
P = 0.005). Neither age nor ER/PgR status was an independent predictor for DFS. Multivariate 
analysis including spCR yielded the same results. The DFS rate was higher among patients with 
pCR than those without pCR (93% vs 82%, P < 0.001) (Figure 3A). Patients who achieved 
spCR had a higher DFS rate than those who did not (96% vs 84%, P < 0.001) (Figure 3B).  
 In the ER/PgR-positive dataset, independent predictors for poorer DFS were advanced 
clinical nodal stage, histological/nuclear grade 3, young age (≤40), and not achieving spCR. 
pCR was not an independent predictor for DFS on multivariate analysis (Table 2; Figure 3C, D). 
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For the ER/PgR-negative dataset, clinical tumor stage and both pCR and spCR were 
independent predictors for DFS (Table 2; Figure 3E, F).  
Predictors for other survival outcomes are listed in Supplementary Table S1. Predictors for 
OS were clinical nodal stage, histological/nuclear grade, and spCR, but pCR was not an 
independent predictor. Predictors for DRFS were clinical nodal stage, histological/nuclear grade, 
young age, pCR, and spCR. 
 
Predictive factors for pCR 
The association of baseline characteristics with pCR/spCR following NAC plus trastuzumab 
was evaluated by multivariate logistic regression (Table 3). In the whole dataset, independent 
predictors for pCR were negative ER/PgR status (adjusted OR 3.42, 95%CI 2.42-4.86, P < 
0.001) and clinical tumor stage T1-2 compared with T3-4 (adjusted OR 1.88, 95%CI 1.27-2.79, 
P = 0.002). Histological/nuclear grade 3 showed a statistically marginal association with pCR 
(adjusted OR 1.39, 95%CI 0.99-1.95, P = 0.060). The same factors were selected as 
independent predictors in the multivariate model for spCR. 
In the ER/PgR-positive dataset, clinical tumor stage was a predictor for pCR and spCR. In 
the ER/PgR-negative dataset, clinical tumor stage was an independent predictor for both pCR 






In this analysis, we assessed survival after NAC plus trastuzumab among patients with 
HER2-positive breast cancer. Although clinical nodal status, histological/nuclear grade, and 
pCR/spCR were independent predictors for DFS, the prognostic impact differed depending on 
ER/PgR status. pCR was a predictor for DFS particularly in patients with ER/PgR-negative 
tumor, and spCR—a stricter definition of pCR—was an independent prognostic factor 
regardless of ER/PgR status. 
Our data included more patients with clinical tumor stage T2 or higher (89%) and clinically 
node positive (67%). In this population, a three-year DFS rate of 87% was relatively good; 
however, a considerable number of patients experienced disease relapse during the follow-up 
period. Risk factors associated with disease relapse need to be clarified to conduct a clinical trial 
aimed at improving these patients’ prognosis. 
In two phase III trials in which patients with HER2-positive disease were randomly allocated 
to NAC with trastuzumab or NAC only, the addition of trastuzumab to NAC resulted in a higher 
pCR rate and improved DFS [11,8]. The pCR rate in our study (51%) is comparable to those 
reported in previous trials of NAC with trastuzumab (30-67%) [7,8,12,10,13-15,9]. In our study, 
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ER/PgR status was the strongest predictor for pCR or spCR. Our results were consistent with 
those of two meta-analyses in which the pCR rate of NAC with trastuzumab was about 50% for 
patients with ER/PgR-negative disease and 30% for those with ER/PgR-positive disease [16,6]. 
In the TECHNO trial, a phase II trial of 217 patients with HER2-positive disease who 
received NAC with trastuzumab, failure to achieve pCR was a significant predictor for DFS in 
the multivariate analysis[10]. Kim et al. retrospectively investigated the prognostic value of 
pCR using data from 229 patients with HER2-positive tumor who were treated with NAC with 
trastuzumab [12]. They reported that pCR, clinical tumor stage, and lymphovascular invasion 
were independent predictors for DFS. In our study, pCR and spCR were predictors for DFS; in 
addition, conventional prognostic factors such as nodal stage and histological/nuclear grade 
were predictors for DFS.  
In this study, the association of age with DFS was not statistically significant in the whole 
dataset, consistent with the results of the TECHNO trial and Kim et al. Partridge et al. reported 
that young age was not associated with worse DFS in patients with HER2-positive disease using 
large cohort data from the HERA trial [17]. When we divided the patients into ER/PgR-positive 
and -negative groups, multivariate analysis showed that young age (age ≤ 40) was an 
independent predictor for poorer DFS in the ER/PgR-positive dataset. Our result was consistent 
with earlier studies showing that younger age is an independent predictor for worse DFS, 
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especially in patients with ER/PgR-positive disease [18,19]. 
After dividing the patients into ER/PgR-positive and -negative datasets, we performed 
multivariate analysis for DFS using each dataset. About 30-40% of HER2-enriched subtype 
tumors are reported to be ER positive [20,21]. Among clinically HER2-positive tumors, up to 
60% are classified as the HER2-enriched subtype, with the rest classified as luminal B, luminal 
A, or basal-like [22]. Adjuvant systemic therapy differs according to ER/PgR status [23]. 
Therefore, it seemed reasonable to perform the analysis based on ER/PgR status; however, the 
results should be interpreted carefully because of the relatively small event rate in each dataset. 
In relation to the two aforementioned meta-analyses, pooled analysis from the German study 
group [6] indicated that pCR was a prognostic factor for the HER2-positive non-luminal 
subgroup, but not for those in the HER2-positive luminal subgroup. In the meta-analysis from 
the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) [16], there was a stronger 
association of pCR with event-free survival in the HER2-positive non-luminal subgroup 
compared with those in the HER2-positive luminal subgroup. In our study, pCR was an 
independent predictor for DFS in the ER/PgR-negative dataset, but not ER/PgR-positive dataset, 
and spCR was an independent predictor for DFS regardless of ER/PgR status. 
The limitations of this study include its retrospective design. Adjustment using multivariate 
analysis is mandatory to minimize selection bias. The relatively short observation period may 
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also limit the interpretation of our results. The median follow-up period of our study (42 
months) covered the time when recurrence risk is high in HER2-positive disease [24]. A 
strength of our study was the large number of patients, which allowed us to conduct multivariate 
analysis separately according to ER/PgR status. 
In conclusion, pCR/spCR, nodal status, and grade were predictors for DFS in patients with 
HER2-positive disease treated with NAC plus trastuzumab. Response to therapy and prognostic 
impact of the factors differed according to ER/PgR status. Our results may help identify patients 
who are not likely to achieve pCR or whose outcome would otherwise be unfavorable. New 
treatment approaches, such as the incorporation of novel anti-HER2 drugs, are needed for 




We thank the patients who participated in this study. We also thank our colleagues who 
participated in this study and are not included in the list of authors, in alphabetical order: Y. 
Hasegawa (Hirosaki Municipal Hospital), K. Hisamatsu (Oikawa Hospital), Y. Horimoto 
(Juntendo University School of Medicine), Y. Kakugawa (Miyagi Cancer Center), A. Kitani 
(Tokyo Kyosai Hospital), Y. Kokawa (Wakayama Medical University), G. Kutomi (Sapporo 
 17 
 
Medical University School of Medicine), Y. Moriguchi (Kyoto City Hospital), T. Morimoto 
(Yao Municipal Hospital), H. Nakagomi (Yamanashi Prefectural Central Hospital), K. Narui 
(Yokohama City University Medical Center), M. Ohara (Hiroshima Prefectural Hospital), T. 
Saito (Saitama Red Cross Hospital), T. Sato (Niigata Prefectural Central Hospital), H. 
Shigematsu (Research Institute for Radiation Biology and Medicine, Hiroshima University), K. 
Shingu (Iida Municipal Hospital), H. Sugiura (Nagoya City West Medical Center), M. 
Takahashi (Hokkaido Cancer Center), H. Takeuchi (National Hospital Organization Beppu 
Medical Center), K. Yamagami (Shinko Hospital), K. Yamazaki (Sapporo-Kotoni Breast Clinic), 
and K. Yoshida (Gifu University Hospital). We appreciate the contributions to data management 
of Tetsuhiro Sakai and Aya Maruyama from the JBCRG data canter.  
 
FUNDING 
This work was supported by research grants from the Ministry of Health, Labour and Welfare of 
Japan (Nos. H18-3JIGAN-IPPAN-007 and H22- GANRINSHO-IPPAN-039). 
 
CONFLICT OF INTEREST 
H. Iwata, S. Ohno, N. Masuda, and S. Morita received honorarium from Chugai Pharmaceutical 
Co., Ltd. N. Masuda received honorarium from Eisai Co., Ltd. M. Toi is currently conducting 
 18 
 
research sponsored by Chugai Pharmaceutical Co., Ltd. and received donation from Chugai 





1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast 
cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. 
Science 235 (4785):177-182 
2. Costa RB, Kurra G, Greenberg L, Geyer CE (2010) Efficacy and cardiac safety of adjuvant 
trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Annals of 
oncology : official journal of the European Society for Medical Oncology / ESMO 21 
(11):2153-2160. doi:10.1093/annonc/mdq096 
3. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R (2012) 
Trastuzumab containing regimens for early breast cancer. Cochrane database of systematic 
reviews (Online) 4:CD006243. doi:10.1002/14651858.CD006243.pub2 
4. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in 
breast cancer: a meta-analysis. Journal of the National Cancer Institute 97 (3):188-194. 
doi:10.1093/jnci/dji021 
5. Mieog JS, van der Hage JA, van de Velde CJ (2007) Preoperative chemotherapy for women 




6. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, 
Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, 
Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response 
on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30 
(15):1796-1804. doi:10.1200/jco.2011.38.8595 
7. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green 
MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, 
Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher 
pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and 
epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor 
receptor 2-positive operable breast cancer. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 23 (16):3676-3685. doi:10.1200/JCO.2005.07.032 
8. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, 
Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok 
A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J (2010) Neoadjuvant 
chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant 
chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH 
 21 
 
trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 
375 (9712):377-384. doi:10.1016/s0140-6736(09)61964-4 
9. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, 
Eidtmann H, Gerber B, Hanusch C, Kuhn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, 
Jackisch C, Kaufmann M, Mehta K, von Minckwitz G (2010) Neoadjuvant treatment with 
trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 28 
(12):2024-2031. doi:10.1200/JCO.2009.23.8451 
10. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, Camara O, 
Muller V, du Bois A, Kuhn T, Stickeler E, Harbeck N, Hoss C, Kahlert S, Beck T, Fett W, Mehta 
KM, von Minckwitz G, Loibl S (2011) Pathologic complete response after neoadjuvant 
chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor 
receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG 
study groups. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 29 (25):3351-3357. doi:10.1200/JCO.2010.31.4930 
11. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green 
MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, 
Hortobagyi GN (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, 
 22 
 
epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human 
epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial 
randomized study population and data of additional patients treated with the same regimen. 
Clinical cancer research : an official journal of the American Association for Cancer Research 
13 (1):228-233. doi:10.1158/1078-0432.CCR-06-1345 
12. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, 
Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA (2013) 
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for 
improved survival in women with HER2-overexpressing breast cancer. Annals of oncology : 
official journal of the European Society for Medical Oncology / ESMO 24 (8):1999-2004. 
doi:10.1093/annonc/mdt131 
13. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, 
Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, 
Huober J, Kuhn T, Nekljudova V, von Minckwitz G (2012) Lapatinib versus trastuzumab in 
combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 
44): a randomised phase 3 trial. The lancet oncology 13 (2):135-144. 
doi:10.1016/s1470-2045(11)70397-7 
14. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh 
 23 
 
P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z, Coccia-Portugal M, 
Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, 
Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M (2012) Lapatinib with trastuzumab for 
HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 
3 trial. Lancet 379 (9816):633-640. doi:10.1016/s0140-6736(11)61847-3 
15. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de 
la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, 
Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of 
neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or 
early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 
trial. The lancet oncology 13 (1):25-32. doi:10.1016/S1470-2045(11)70336-9 
16. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron 
D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, 
Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann 
H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE, Pazdur R, 
Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and 




17. Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Winer EP, 
Gelber RD (2013) Effect of age on breast cancer outcomes in women with human epidermal 
growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. Journal 
of clinical oncology : official journal of the American Society of Clinical Oncology 31 
(21):2692-2698. doi:10.1200/JCO.2012.44.1956 
18. Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W, Korean Breast Cancer S (2007) 
Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen 
resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25 
(17):2360-2368. doi:10.1200/JCO.2006.10.3754 
19. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R, Viale G, 
Pruneri G, Veronesi P, Luini A, Intra M, Cardillo A, Torrisi R, Rocca A, Goldhirsch A (2006) 
Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) 
with operable breast cancer and node negative disease. Annals of oncology : official journal of 
the European Society for Medical Oncology / ESMO 17 (10):1497-1503. 
doi:10.1093/annonc/mdl145 
20. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, 
Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, 
 25 
 
Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on 
intrinsic subtypes. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology 27 (8):1160-1167. doi:10.1200/JCO.2008.18.1370 
21. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de 
Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, 
Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor 
subclasses with clinical implications. Proceedings of the National Academy of Sciences of the 
United States of America 98 (19):10869-10874. doi:10.1073/pnas.191367098 
22. Perou CM (2011) Molecular stratification of triple-negative breast cancers. Oncologist 16 
Suppl 1:61-70. doi:10.1634/theoncologist.2011-S1-61 
23. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ, 
Panel m (2013) Personalizing the treatment of women with early breast cancer: highlights of the 
St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. 
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 24 
(9):2206-2223. doi:10.1093/annonc/mdt303 
24. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, Gelber RD, 
Castiglione-Gertsch M, Coates AS, Goldhirsch A, Cardoso F (2013) Patterns of Recurrence and 
outcome according to breast cancer subtypes in lymph node-negative disease: results from 
 26 
 
international breast cancer study group trials VIII and IX. Journal of clinical oncology : official 






Table 1. Patient, disease, and treatment characteristics 
Factors n (%) 
All cases 776 (100) 
Age   
Median (Min-Max) 53 (25-70) 
BMI   
Median (Min-Max) 22.0 (15.0-47.3) 
Unknown 2 (0.3) 
Menopausal status   
Pre-menopausal 335 (43.2) 
Post-menopausal 422 (54.4) 
Unknown 19 (2.4) 
Clinical tumor size   
T1b 9 (1.2) 
T1c 77 (9.9) 
T2 476 (61.3) 
T3 122 (15.7) 
 28 
 
T4 91 (11.7) 
Unknown 1 (0.1) 
Clinical nodal status   
N0 252 (32.5) 
N1 366 (47.2) 
N2 103 (13.3) 
N3 54 (7) 
Unknown 1 (0.1) 
ER/PgR status   
Positive 334 (43) 
Negative 439 (56.6) 
Unknown 3 (0.4) 
Histological/Nuclear grade   
1 107 (13.8) 
2 184 (23.7) 
3 350 (45.1) 
Unknown 135 (17.4) 
NAC regimen   
 29 
 
Anthracycline and taxane 676 (87.1) 
Taxane only 78 (10.1) 
Anthracycline only 7 (0.9) 
Others 1 (0.1) 
Unknown 14 (1.8) 
Local therapy   
Mastectomy+XRT 96 (12.4) 
Mastectomy alone 181 (23.3) 
BCS+XRT 449 (57.9) 
BCS alone 44 (5.7) 
Needle biopsy+XRT 1 (0.1) 
Needle biopsy alone 1 (0.1) 
Unknown 4 (0.5) 
pCR (ypT0/is+ypN0)   
Yes 399 (51.4) 
No 365 (47) 
Unknown 12 (1.5) 
spCR (ypT0+ypN0)   
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Yes 240 (30.9) 
No 525 (67.7) 
Unknown 11 (1.4) 
Adjuvant hormonal therapy   
Yes 281 (36.2) 
No 440 (56.7) 
Unknown 55 (7.1) 
Adjuvant trastuzumab therapy   
Yes 697 (89.8) 
No 65 (8.4) 
Unknown 14 (1.8) 
Adjuvant chemotherapy   
Yes 45 (5.8) 
No 720 (92.8) 
Unknown 11 (1.4) 
BMI, body mass index; ER/PgR, estrogen receptor/progesterone receptor; NAC, neoadjuvant 





Table 2. Adjusted hazard ratios of factors predicting DFS 
  pCR (ypT0/is+ypN0) spCR (ypT0+ypN0) 
Factor HR 95%CI p-value HR 95%CI p-value 
Whole dataset       
Age       
≤40 vs >40 1.67 (0.95-2.81) 0.074 1.63 (0.93-2.75) 0.088 
BMI       
25≤ vs <22 1.31 (0.74-2.24) 0.351 1.31 (0.74-2.24) 0.348 
22≤, <25 vs <22 0.96 (0.56-1.61) 0.891 1.00 (0.58-1.67) 0.993 
Clinical tumor size       
T3-4 vs T1-2 1.53 (0.93-2.49) 0.093 1.42 (0.87-2.32) 0.160 
Clinical nodal status       
N2-3 vs N0 2.63 (1.36-5.21) 0.004 2.58 (1.34-5.12) 0.004 
N1 vs N0 1.64 (0.91-3.09) 0.100 1.73 (0.96-3.26) 0.070 
ER/PgR       
Negative vs positive 0.97 (0.47-2.08) 0.933 0.93 (0.46-1.96) 0.842 
Histological/Nuclear grade       
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3 vs 1&2 1.81 (1.15-2.91) 0.011 1.77 (1.12-2.84) 0.014 
pCR/spCR       
non-pCR vs pCR 1.98 (1.22-3.24) 0.005 2.90 (1.57-5.90) <0.001 
ER/PgR-positive dataset             
Age             
≤40 vs >40 2.40 (1.12-4.94) 0.026 2.33 (1.08-4.80) 0.031 
BMI             
25≤ vs <22 1.49 (0.63-3.38) 0.354 1.54 (0.66-3.45) 0.313 
22≤, <25 vs <22 0.69 (0.25-1.67) 0.419 0.69 (0.25-1.68) 0.433 
Clinical tumor size             
T3-4 vs T1-2 0.83 (0.35-1.88) 0.653 0.69 (0.28-1.62) 0.399 
Clinical nodal status             
N2-3 vs N0 4.26 (1.53-13.14) 0.005 4.54 (1.62-14.13) 0.004 
N1 vs N0 2.55 (0.99-7.43) 0.053 2.83 (1.08-8.39) 0.034 
Histological/Nuclear grade             
3 vs 1&2 3.09 (1.48-6.62) 0.003 3.14 (1.49-6.85) 0.003 
pCR/spCR             
non-pCR vs pCR 1.20 (0.57-2.69) 0.634 3.86 (1.13-24.21) 0.029 
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ER/PgR-negative dataset       
Age       
≤40 vs >40 0.95 (0.35-2.18) 0.913 1.01 (0.38-2.28) 0.979 
BMI       
25≤ vs <22 0.94 (0.39-2.05) 0.886 0.97 (0.40-2.11) 0.942 
22≤, <25 vs <22 1.10 (0.56-2.08) 0.774 1.10 (0.56-2.08) 0.779 
Clinical tumor size       
T3-4 vs T1-2 2.20 (1.16-4.20) 0.017 2.11 (1.11-4.04) 0.024 
Clinical nodal status       
N2-3 vs N0 2.04 (0.85-5.07) 0.112 1.73 (0.73-4.27) 0.217 
N1 vs N0 1.49 (0.70-3.38) 0.306 1.39 (0.66-3.13) 0.398 
Histological/Nuclear grade       
3 vs 1&2 1.33 (0.74-2.48) 0.354 1.29 (0.72-2.41) 0.393 
pCR/spCR       
non-pCR vs pCR 2.63 (1.43-4.90) 0.002 2.66 (1.31-5.97) 0.006 
BMI, body mass index; ER/PgR, estrogen receptor/progesterone receptor; pCR, pathologic 




Table 3. Adjusted odds ratios of factors predicting pCR 
  pCR (ypT0/is+ypN0) spCR (ypT0+ypN0) 
Factor OR 95%CI p-value OR 95%CI p-value 
Whole dataset       
Age       
>40 vs ≤40 0.97 (0.60-1.58) 0.907 1.45 (0.84-2.63) 0.191 
BMI       
25≤ vs <22 1.22 (0.78-1.91) 0.388 1.31 (0.80-2.11) 0.280 
22≤, <25 vs <22 1.38 (0.94-2.04) 0.100 1.47 (0.98-2.21) 0.062 
Clinical tumor size       
T1-2 vs T3-4 1.88 (1.27-2.79) 0.002 2.16 (1.39-3.41) 0.001 
Clinical nodal status       
N0 vs N2-3 0.65 (0.40-1.07) 0.093 0.98 (0.57-1.71) 0.942 
N1 vs N2-3 0.83 (0.53-1.31) 0.435 1.44 (0.88-2.39) 0.152 
ER/PgR status       
Negative vs positive 3.42 (2.42-4.86) <0.001 2.27 (1.55-3.35) <0.001 
Histological/Nuclear grade       
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3 vs 1&2 1.39 (0.99-1.95) 0.060 1.29 (0.90-1.88) 0.169 
ER/PgR-positive dataset             
Age             
>40 vs ≤40 0.74 (0.40-1.39) 0.343 1.22 (0.56-2.89) 0.622 
BMI             
25≤ vs <22 1.65 (0.85-3.20) 0.140 1.27 (0.56-2.81) 0.559 
22≤, <25 vs <22 1.43 (0.77-2.61) 0.253 1.46 (0.71-2.97) 0.296 
Clinical tumor size             
T1-2 vs T3-4 1.76 (0.94-3.43) 0.078 2.95 (1.28-7.72) 0.010 
Clinical nodal status             
N0 vs N2-3 0.98 (0.46-2.11) 0.954 0.89 (0.36-2.32) 0.810 
N1 vs N2-3 0.80 (0.39-1.67) 0.547 0.93 (0.39-2.35) 0.869 
Histological/Nuclear grade             
3 vs 1&2 1.22 (0.73-2.05) 0.454 1.00 (0.54-1.86) 0.991 
ER/PgR-negative dataset       
Age       
>40 vs ≤40 1.43 (0.68-2.94) 0.344 1.73 (0.80-4.08) 0.170 
BMI       
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25≤ vs <22 0.95 (0.52-1.76) 0.871 1.29 (0.69-2.36) 0.422 
22≤, <25 vs <22 1.35 (0.81-2.27) 0.248 1.47 (0.89-2.43) 0.132 
Clinical tumor size       
T1-2 vs T3-4 1.93 (1.17-3.20) 0.010 1.89 (1.13-3.24) 0.016 
Clinical nodal status       
N0 vs N2-3 0.48 (0.24-0.92) 0.027 0.98 (0.49-1.95) 0.943 
N1 vs N2-3 0.89 (0.48-1.61) 0.692 1.75 (0.97-3.26) 0.065 
Histological/Nuclear grade       
3 vs 1&2 1.53 (0.97-2.42) 0.068 1.50 (0.94-2.40) 0.087 
BMI, body mass index; ER/PgR, estrogen receptor/progesterone receptor; pCR, pathologic 





Figure 1. Flowchart of data collection and analysis 
Figure 2. DFS curves of the (A) whole dataset and (B) ER/PgR-positive and -negative datasets 
Figure 3. DFS curves of patients with pCR (ypT0/is + ypN0) versus non-pCR in the (A) whole 
dataset, (C) ER/PgR-positive dataset, and (E) ER/PgR-negative dataset. DFS curves of patients 
with spCR (ypT0 + ypN0) versus non-spCR in the (B) whole dataset, (D) ER/PgR-positive 












Table S1. Summary of P-values of clinicopathological factors by the multivariate Cox 
regression for survival outcomes 
 
  DFS OS DRFS 
Factor P P P 
Age (years) 
   
≤40 vs >40 0.074 0.112 0.027 
BMI 
   
25≤ vs <22 0.351 0.149 0.465 
22≤, <25 vs <22 0.891 0.793 0.672 
Clinical tumor size 
   
T3-4 vs T1-2 0.093 0.591 0.098 
Clinical nodal status 
   
N2-3 vs N0 0.004 0.003 0.042 
N1 vs N0 0.100 0.006 0.128 
ER/PgR 
   
Negative vs Positive 0.933 0.137 0.450 
Histological/Nuclear grade 
   
3 vs 1&2 0.011 0.032 0.018 
pCR 
   
non-pCR vs pCR 0.005 0.246 0.002 
Age (years)       
≤40 vs >40 0.088 0.156 0.026 
BMI 
   
25≤ vs <22 0.348 0.159 0.502 
22≤, <25 vs <22 0.993 0.857 0.681 
Clinical tumor size 
   
T3-4 vs T1-2 0.160 0.725 0.147 
Clinical nodal status 
   
N2-3 vs N0 0.004 0.002 0.048 
N1 vs N0 0.070 0.004 0.101 
ER/PgR 
   
Negative vs Positive 0.842 0.148 0.380 
Histological/Nuclear grade 
   
3 vs 1&2 0.014 0.044 0.025 
spCR 
   
non-pCR vs pCR <0.001 0.048 0.001 
BMI, body mass index; DFS, disease-free survival; DRFS, distant recurrence-free survival; 
ER/PgR, estrogen receptor/progesterone receptor; OS, overall survival; pCR, pathologic 
complete response; spCR, strict pathologic complete response. 
 
